Recent advances in mesalamine colonic delivery systems

Abstract Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing potential side effects. Mesalamine is a...

Full description

Bibliographic Details
Main Authors: Mohammad F. Bayan, Rana F. Bayan
Format: Article
Language:English
Published: SpringerOpen 2020-07-01
Series:Future Journal of Pharmaceutical Sciences
Subjects:
Online Access:http://link.springer.com/article/10.1186/s43094-020-00057-7
id doaj-42812c68c4a54e01af79c2760e2afb6d
record_format Article
spelling doaj-42812c68c4a54e01af79c2760e2afb6d2020-11-25T02:57:36ZengSpringerOpenFuture Journal of Pharmaceutical Sciences2314-72532020-07-01611710.1186/s43094-020-00057-7Recent advances in mesalamine colonic delivery systemsMohammad F. Bayan0Rana F. Bayan1Faculty of Pharmacy, Philadelphia UniversityFaculty of Pharmacy, Philadelphia UniversityAbstract Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing potential side effects. Mesalamine is a class IV drug, according to the Biopharmaceutics Classification System, used usually to treat inflammation associated with colon related diseases such as Crohn’s disease and ulcerative colitis. Main text An ideal colon targeting system aims to deliver a therapeutic agent, selectively and effectively, to the colon. This system should ideally retain the drug release in the upper GI tract (stomach and small intestine); while trigger the drug release in the colon. Several approaches have been used to fabricate formulations to achieve a colon specific delivery of mesalamine such as; time dependent, pH responsive, enzymatic/microbial responsive and ultrasound mediated approaches. This overview outlines the recent advances in mesalamine-colon delivery approaches for the potential treatment of ulcerative colitis and Crohn’ disease. Conclusion A combined pH-time dependent delivery system can improve mesalamine colonic drug delivery via employing carriers capable of retarding mesalamine release in the stomach and delivering it at predetermined time points after entering the intestine. The existence of specific enzymes, produced by various anaerobic bacteria present in the colon advocates the advantage of designing enzyme sensitive systems and combining it with pH-time dependent system to improve mesalamine colonic delivery. The use of ultrasound has shown promises to effectively treat inflammatory bowel diseases.http://link.springer.com/article/10.1186/s43094-020-00057-7Mesalamine5-amino salicylic acidMesalazineCrohn’s diseaseUlcerative colitis
collection DOAJ
language English
format Article
sources DOAJ
author Mohammad F. Bayan
Rana F. Bayan
spellingShingle Mohammad F. Bayan
Rana F. Bayan
Recent advances in mesalamine colonic delivery systems
Future Journal of Pharmaceutical Sciences
Mesalamine
5-amino salicylic acid
Mesalazine
Crohn’s disease
Ulcerative colitis
author_facet Mohammad F. Bayan
Rana F. Bayan
author_sort Mohammad F. Bayan
title Recent advances in mesalamine colonic delivery systems
title_short Recent advances in mesalamine colonic delivery systems
title_full Recent advances in mesalamine colonic delivery systems
title_fullStr Recent advances in mesalamine colonic delivery systems
title_full_unstemmed Recent advances in mesalamine colonic delivery systems
title_sort recent advances in mesalamine colonic delivery systems
publisher SpringerOpen
series Future Journal of Pharmaceutical Sciences
issn 2314-7253
publishDate 2020-07-01
description Abstract Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing potential side effects. Mesalamine is a class IV drug, according to the Biopharmaceutics Classification System, used usually to treat inflammation associated with colon related diseases such as Crohn’s disease and ulcerative colitis. Main text An ideal colon targeting system aims to deliver a therapeutic agent, selectively and effectively, to the colon. This system should ideally retain the drug release in the upper GI tract (stomach and small intestine); while trigger the drug release in the colon. Several approaches have been used to fabricate formulations to achieve a colon specific delivery of mesalamine such as; time dependent, pH responsive, enzymatic/microbial responsive and ultrasound mediated approaches. This overview outlines the recent advances in mesalamine-colon delivery approaches for the potential treatment of ulcerative colitis and Crohn’ disease. Conclusion A combined pH-time dependent delivery system can improve mesalamine colonic drug delivery via employing carriers capable of retarding mesalamine release in the stomach and delivering it at predetermined time points after entering the intestine. The existence of specific enzymes, produced by various anaerobic bacteria present in the colon advocates the advantage of designing enzyme sensitive systems and combining it with pH-time dependent system to improve mesalamine colonic delivery. The use of ultrasound has shown promises to effectively treat inflammatory bowel diseases.
topic Mesalamine
5-amino salicylic acid
Mesalazine
Crohn’s disease
Ulcerative colitis
url http://link.springer.com/article/10.1186/s43094-020-00057-7
work_keys_str_mv AT mohammadfbayan recentadvancesinmesalaminecolonicdeliverysystems
AT ranafbayan recentadvancesinmesalaminecolonicdeliverysystems
_version_ 1724710252052480000